From our Center

Articles, News, Press Releases

Spring 2018

Vinicio de Jesus Perez, MD

I’m Aware That I’m Rare: Vinicio A. de Jesus Perez, MD

Dr. Vinicio de Jesus Perez discusses the 4th International Symposium: From Precision Biology to Precision Medicine in Pulmonary Hypertension taking place Friday, May 18, 2018.

James Spudich, PhD
Mark Krasnow, MD, PhD

Stanford researchers, including Vera Moulton Wall Center Executive Director, Mark Krasnow, MD, PhD, map intricacies of lung cancer in one of their own

When James Spudich was diagnosed with lung cancer, researchers had a rare, and unexpected, opportunity to study healthy and diseased human tissue at an unprecedented level of detail.

It was around 3 p.m. on a Thursday last October when James Spudich and Suzanne Pfeffer poked their heads into the office of Mark Krasnow, on the fourth floor of the Beckman Center for Molecular and Genetic Medicine, interrupting a meeting he was having with a colleague.

“Can we talk to you for a minute?” Pfeffer said.

James Spudich, PhD
Mark Krasnow, MD, PhD

Dr. Kristina Kudelko featured on 'Stars of Stanford Medicine'

Kristina Kudelko, MD, clinical associate professor of medicine, expected to return to New York after a fellowship in pulmonary hypertension, but she unexpectedly fell in love with Stanford and has called it home since 2008.

Why did you go into medicine?

I thought that I was going to do something in the humanities. I liked music but I wasn’t talented enough to have a career in it. I thought about journalism too. But I got swept up into intro to bio classes that I took just to fill requirements at Yale. I became really interested in biology, and thought maybe I would do marine biology.

In the end, a huge component was my brother. He’s a role model for me and a neurologist. It seemed like a good fit. I did a year of research at the National Institutes of Health, but realized I really liked the clinical side.

Vinicio de Jesus Perez, MD
and Roham Zamanian, MD

Congratulations to Dr. Roham Zamanian, Dr. Vinicio de Jesus Perez, and dedicated Wall Center clinicians, researchers and staff, for publishing in the Blue Journal (American Journal of Respiratory and Critical Care Medicine, March 2018), as well as the American Journal of Physiology-Lung Cellular and Molecular Physiology (February, 2018). 

Dr. Zamanian and Dr. de Jesus Perez, et al, recently published “Drug Induced Pulmonary Arterial Hypertension: A Primer for Clinicians and Scientists”, in the February issue of the American Journal of Physiology-Lung Cellular and Molecular Physiology. However, the largest PH community impact is felt by the American Journal of Respiratory and Critical Care Medicine paper, titled “Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension”.   More Along with significant contributions from our Wall Center clinical and research team (contributing authors include : Hedlin, Greuenwald, Wilson, Segal, Jorden, Kudelko, Liu, His, Rupp, Sweatt, Tuder, Berry, Rabinovitch, Doyle, and Kawut), this new research has changed the established worldwide guidelines for PH, and was recently highlighted at the 6th World Symposium on Pulmonary Hypertension in Nice, France. 

Additionally, Dr. Vinicio de Jesus Perez, Assistant Professor of Medicine and Staff Physician for the Stanford Adult Pulmonary Hypertension Clinic, was honored with a visiting professorship at Brown Alpert Medical School (March, 2018), where he presented Grand Rounds and led a round table discussion on “Drug Induced Pulmonary Hypertension: A Primer for Clinicians and Scientists”.


Vinicio de Jesus Perez, MD
Jair Tenorio, PhD

Stanford-Spain form Consortium for discovery of novel genes associated with risk of PAH

The main aim of this consortium is to perform WES analysis in PAH patients seen at Hospital La Paz in Madrid and Stanford hospital to identify novel gene variants potentially involved in PAH. Work by the consortium so far has led to the discovery of CRIPAK, a key protein responsible for regulation of pulmonary vascular repair. High risk variants have been found in a high significant percentage of PAH patients independently evaluated in each institution in compare to controls. Validation of CRIPAK at the de Jesus Perez Lab in Stanford has revealed that CRIPAK could contribute to PAH by reducing endothelial viability, promoting small vessel loss and accelerating vascular remodeling. Ongoing analysis of genetic data will likely continue to identify and validate gene modifiers that could serve as potential targets for development of novel therapies for PAH.

Kristina Kudelko, MD, Michelle Fox and Lori Barth

The Wall Center Participates at the Wellness Fair

The Wall Center participated in the 14th annual Wellness Fair on March 22, 2018 at the Arrillaga Center for Sports and Recreation. With over 3500 people in attendance, the Wellness Fair is a celebration of wellness and healthy lifestyle choices. Both Wall Center faculty and staff were on-hand to answer questions about the center, pulmonary hypertension and to promote the 18th Race Against PH

Subscribe to our eNews

Past News